Market Place
Sourcing Support
FDA Confirms Para IV Patent for (Dojolvi) Triheptanoin Oral Liquid
26 Aug 2024 //
FDA
Ultragenyx, Dojolvi Gets Approval in Brazil for Fatty Acid Oxidation Disorders
23 Aug 2021 //
GLOBENEWSWIRE
Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin)
17 Feb 2021 //
PRESS RELEASE
Ultragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin)
22 Jul 2020 //
GLOBENEWSWIRE
Orsini Services Expands Partnership With Ultragenyx To Provide Dojolvi™
10 Jul 2020 //
PRNEWSWIRE
FDA backs second rare disease drug from Ultragenyx in the space of a fortnight
04 Jul 2020 //
PHARMAPHORUM
PANTHERx® Rare Pharmacy Selected by Ultragenyx Pharma to Distribute DOJOLVI™
03 Jul 2020 //
PRNEWSWIRE
FDA Approvals Roundup: Fintepla, Dojolvi, Phesgo
02 Jul 2020 //
RAPS
Ultragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin)
30 Jun 2020 //
PRESS RELEASE
FDA accepts Ultragenyx`s triheptanoin NDA for rare oxidation disorders
14 Oct 2019 //
SEEKINGAPLPHA
This Biotech Is Flirting With A Breakout After FDA Decision On Drug
29 Aug 2018 //
INVESTORS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.